Brain cell connections and the cells themselves degenerate and die, eventually destroying memory and other important mental functions.
No cure exists, but medications and management strategies may temporarily improve symptoms.
Early diagnosis could save up to $7.9 trillion in medical and care costs, emphasizing the significant impact on healthcare systems.
Worldwide multidisciplinary research of the genetics and molecular pathogenesis of Alzheimer’s disease (AD) indicate that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed
There is a growing demand for noninvasive, cost effective diagnostic tools that can detect Alzheimer's at an earlier stage.
Biomarker Assessment Device
Early intervention can maximize the net benefit of treatment by up to 17% for each year the diagnosis is advanced
Saliva based tests are less invasive than blood tests or lumbar punctures.
Our technology can detect biomarkers years before symptoms.
Disease-modifying treatments, especially when initiated during the asymptomatic or very early stages of AD, can delay disease progression and improve symptoms.
Early detection allows for better care planning, improved quality of life, and delays in disease progression, reducing the emotional and financial burden on families
Fabian Maclaren is a seasoned executive with 17 years of experience in the biotech, pharmaceutical, and personal care industries. He specializes in brand development, marketing, and expansion, with a strong track record of successful exits, including a $500 million exit for a 4-year-old brand. Fabian has excelled in capturing international market share, generating $700 million through 50+ partnerships. He also maintains valuable retail relationships resulting in $300 million in domestic wholesale sales. Additionally, he leverages influencer networks and online partnerships, boasting a consumer database of over 250 million contacts.
George brings 25 years of visionary branding, packaging, digital marketing and e-commerce. He meticulously brings products to life through immaculate and cutting-edge design that inspires. Driven by passion and innovation, George Gallo, Founder of his award-winning agency The George Gallo Company, has developed impeccable products for an arsenal of globally recognized brands including LVMH, Target, Fendi & Westfield and more. He is guided by a vision to push the boundaries of creativity and fuse technology and design.
Launch over 500 Products globally.
Ph.D. in Organic Chemistry and MBA from University of Wisconsin, Madison
25 years of C-level experience and key management positions in pharmaceutical
During his time as President at SPL (Scientific Protein Laboratories LLC), Yan led the company to triple net income
Played a pivotal role in multiple rounds of M&A and “change of control” transactions totaling over $1Billion
Ph.D. in Organic Chemistry from the University of Newcastle-Upon-Tyne, UK and a Postdoctoral Fellowship at the University of Victoria, BC, Canada
He has over 35 years of experience in the clinical diagnostic and pharmaceutical industries combined during of which he has held C-level positions
Dr. Slowey has 45 publications in peer-reviewed journals, including seven published book chapters, seventeen (17) issued patents, ten (10) filed patent applications
Has made a number of oral presentations at key scientific symposia on a variety of subjects including HIV diagnosis, liquid biopsy testing for cancer diagnosis, nucleic acid testing, the status of oral fluid testing, the Japanese Healthcare Business and Thyrotropin Receptor Antibody Assays for the Diagnosis of Graves’ Disease.
By enabling earlier detection, this innovative technology could facilitate timely interventions, slowing the progression of the disease and significantly improving patient outcomes.
As a result, millions of individuals worldwide could benefit from more personalized treatment plans, ultimately reducing the burden on healthcare systems and enhancing the quality of life for those affected by Alzheimer's disease.
